Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 14/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.61 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995014 | 0.93 | MAPKAPK2 (1.00) | MAPKAPK2MAPK1MAP2K1RPS6KA3NAMPT | |
| SCHEMBL2994749 | 0.90 | MAPKAPK2 (0.82) | MAPKAPK2MAPK1MAP2K1RPS6KA3NAMPT | |
| SCHEMBL2999523 | 0.89 | MAPKAPK2 (0.80) | MAPKAPK2MAPK1MAP2K1RPS6KA3NAMPT | |
| SCHEMBL2996302 | 0.86 | MAPKAPK2 (0.75) | MAPKAPK2MAPK1MAP2K1RPS6KA3NAMPT | |
| SCHEMBL2998184 | 0.82 | MAPKAPK2 (1.00) | MAPKAPK2MAPK1MAP2K1RPS6KA3 | |
| SCHEMBL2996144 | 0.80 | MAPKAPK2 (0.89) | MAPKAPK2MAPK1MAP2K1RPS6KA3NAMPT | |
| SCHEMBL2987036 | 0.79 | MAPKAPK2 (0.87) | MAPKAPK2MAPK1MAP2K1RPS6KA3NAMPT | |
| SCHEMBL13248590 | 0.79 | MAPKAPK2 (0.64) | MAPKAPK2MAPK1 | |
| SCHEMBL2992197 | 0.78 | MAPKAPK2 (0.75) | MAPKAPK2MAPK1MAP2K1RPS6KA3 | |
| SCHEMBL2998498 | 0.78 | MAPKAPK2 (0.75) | MAPKAPK2MAPK1MAP2K1NAMPTCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885MAPK1 33/4885MAP2K1 65/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | MAPKAPK2 1/4885MAPK1 33/4885MAP2K1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.